Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pai.14275 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary bladder diffuse large B-cell lymphoma: A rare case report.
Int J Surg Case Rep
September 2025
Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Yunnan Province, China. Electronic address:
Introduction: Diffuse large B-cell lymphoma (DLBCL), a common subtype of non-Hodgkin lymphoma (NHL), originates primarily from lymph nodes, with a small proportion arising extranodally in sites such as the gastrointestinal tract and central nervous system. Given the general absence of lymphoid tissue in the bladder, primary bladder DLBCL is exceptionally rare.
Case Presentation: This case report describes an 83-year-old male patient with a bladder mass, initially suspected as cystitis glandularis, ultimately diagnosed via pathological examination as DLBCL.
Primary diffuse large B-cell lymphoma of non-germinal center type with BCL-6 positivity in the kidney: A case report.
Int J Surg Case Rep
August 2025
Department of Urology, The Fourth Affiliated Hospital of Dali University, Chuxiong, Yunnan 675000, China. Electronic address:
Introduction And Importance: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, yet primary renal involvement is rare, constituting less than 1 % of renal malignancies. A case of non-germinal center B-cell-like (non-GCB) DLBCL with BCL-6 positivity is particularly unique. Conventionally, BCL-6 is linked to germinal center B-cell-like (GCB) subtypes.
View Article and Find Full Text PDFTumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.
Blood Adv
September 2025
BC Cancer, Vancouver, British Columbia, Canada.
Classical Hodgkin Lymphoma (CHL) is characterized by a complex tumor microenvironment (TME) that supports disease progression. While immune cell recruitment by Hodgkin and Reed-Sternberg (HRS) cells is well-documented, the role of non-malignant B cells in relapse remains unclear. Using single-cell RNA sequencing (scRNA-seq) on paired diagnostic and relapsed CHL samples, we identified distinct shifts in B-cell populations, particularly an enrichment of naïve B cells and a reduction of memory B cells in early-relapse compared to late-relapse and newly diagnosed CHL.
View Article and Find Full Text PDFNodular lymphocyte-predominant Hodgkin's lymphoma often follows an indolent course but carries a risk of late recurrence and transformation. Given its rarity, there is significant variability in the treatment patterns at various healthcare centers. This retrospective chart review aimed to compare the patient characteristics and outcomes of NLPHL patients >18 years of age diagnosed between January 1st, 2007, and December 31st, 2022, at Parkland Health, the safety-net system for uninsured/underinsured patients in Dallas County, with patients treated at the neighboring NCI-designated Harold C.
View Article and Find Full Text PDFBroad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer.
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.